pSLQ5079_pHR_PGK_sfGFP_CoV-F1 Citations (1)

Originally described in: Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, Chemparathy A, Chmura S, Heaton NS, Debs R, Pande T, Endy D, La Russa MF, Lewis DB, Qi LS Cell. 2020 May 14;181(4):865-876.e12. doi: 10.1016/j.cell.2020.04.020. Epub 2020 Apr 29. PubMed Journal

---

Articles Citing pSLQ5079_pHR_PGK_sfGFP_CoV-F1

Articles
Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms. Tian S, Liu Y, Appleton E, Wang H, Church GM, Dong M. Cell Rep. 2022 Mar 8;38(10):110476. doi: 10.1016/j.celrep.2022.110476. PubMed

If you have published an article using this material, please email us at to have your article added to this page.